Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy …
MC Genovese, K Kalunian, JE Gottenberg… - Jama, 2019 - jamanetwork.com
Importance Patients with active rheumatoid arthritis (RA) despite treatment with biologic
disease-modifying antirheumatic drug (bDMARD) therapy need treatment options. Objective
To evaluate the effects of filgotinib vs placebo on the signs and symptoms of RA in a
treatment-refractory population. Design, Setting, and Participants A 24-week, randomized,
placebo-controlled, multinational phase 3 trial conducted from July 2016 to June 2018 at
114 sites internationally, randomizing 449 adult patients (and treating 448) with moderately …
disease-modifying antirheumatic drug (bDMARD) therapy need treatment options. Objective
To evaluate the effects of filgotinib vs placebo on the signs and symptoms of RA in a
treatment-refractory population. Design, Setting, and Participants A 24-week, randomized,
placebo-controlled, multinational phase 3 trial conducted from July 2016 to June 2018 at
114 sites internationally, randomizing 449 adult patients (and treating 448) with moderately …
